You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

ARIMIDEX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Arimidex, and what generic alternatives are available?

Arimidex is a drug marketed by Ani Pharms and is included in one NDA.

The generic ingredient in ARIMIDEX is anastrozole. There are twenty-four drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the anastrozole profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Arimidex

A generic version of ARIMIDEX was approved as anastrozole by ACCORD HLTHCARE on June 28th, 2010.

  Try a Trial

Drug patent expirations by year for ARIMIDEX
Drug Prices for ARIMIDEX

See drug prices for ARIMIDEX

Recent Clinical Trials for ARIMIDEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Translational Breast Cancer Research Consortium (TBCRC)Phase 2
Jose Pablo LeonePhase 2
Novartis PharmaceuticalsPhase 2

See all ARIMIDEX clinical trials

Pharmacology for ARIMIDEX
Drug ClassAromatase Inhibitor
Mechanism of ActionAromatase Inhibitors

US Patents and Regulatory Information for ARIMIDEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms ARIMIDEX anastrozole TABLET;ORAL 020541-001 Dec 27, 1995 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ARIMIDEX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0296749 SPC/GB96/004 United Kingdom ⤷  Try a Trial PRODUCT NAME: ANASTROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT; REGISTRATION NO/DATE: UK 12619/0106 19950811
0296749 09C0055 France ⤷  Try a Trial PRODUCT NAME: ANASTROZOLE, EVENTUELLEMENT SOUS LA FORME D’UN SEL D’ADDITION ACCEPTABLE EN MEDECINE PHARMACEUTIQUE; REGISTRATION NO/DATE IN FRANCE: NL 21126 DU 19961227; REGISTRATION NO/DATE AT EEC: 12619/0106 DU 19950811
0296749 C970012 Netherlands ⤷  Try a Trial PRODUCT NAME: ANASSTROZOLUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; NAT. REGISTRATION NO/DATE: RVG 19123 19960905; FIRST REGISTRATION: GB 12619/0106 19950811
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.